Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenamine Caffeine Tablets (酚氨咖敏片) is a multi-ingredient oral OTC medication manufactured by Sinopharm Xingsha Pharmaceuticals (Xiamen) for the symptomatic relief of the common cold, fever, headache, and neuralgia. The combination consists of four active pharmaceutical ingredients: **paracetamol** and **aminopyrine**, which serve as antipyretics and analgesics by inhibiting cyclooxygenase (COX) enzymes and reducing prostaglandin synthesis; **caffeine**, a central nervous system stimulant that enhances the analgesic effect and counteracts drowsiness; and **chlorpheniramine maleate**, an H1-receptor antagonist that alleviates allergic-like symptoms such as rhinorrhea, sneezing, and watery eyes. This formulation is a standard generic product in the Chinese consumer health market for rapid relief of upper respiratory infection symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + aminopyrine + caffeine + chlorpheniramine maleate.